Novavax, Inc.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”), of the important January 11, 2022 lead plaintiff deadline.

If you purchased Novavax securities between March 2, 2021 and October 19, 2021 and would like to join the action, please click “Join This Class Action.”

集体诉讼期:March 2, 2021 through October 19, 2021
If you purchased Novavax securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373 (the Company’s product candidate as a vaccine for COVID-19);
  • as a result, Novavax was unlikely to meet its anticipated Emergency Use Authorization (EUA) regulatory timelines for NVX-CoV2373;
  • accordingly, the Company overstated the regulatory and commercial prospects for NVX-CoV2373; and
  • as a result, the Company’s public statements were materially false and misleading at all relevant times as a result of the foregoing, defendants’ public statements were materially false and/or misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.



自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。